Vectus Biosystems shareholders approve all AGM resolutions as company advances VB0004 partnering strategy
VBS: $0.079 -1.25% · MC: $4M
Vectus Biosystems says it is prioritising idiopathic pulmonary fibrosis for lead drug candidate VB0004 and is building patient data to support its intended partnering strategy; the supplied CEO address is truncated before its full outlook is provided. The company also reported lower operating costs, a recent placement and an R&D tax rebate, while all AGM resolutions were passed, including approvals for a placement facility and employee incentive plan.

Comments